|
1
|
Basu A and Tu H: Activation of ERK during
DNA damage-induced apoptosis involves protein kinase Cdelta.
Biochem Biophys Res Commun. 334:1068–1073. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu D, Chen B, Parihar K, et al: ERK
activity facilitates activation of the S-phase DNA damage
checkpoint by modulating ATR function. Oncogene. 25:1153–1164.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang S, Gao J, Lei Q, et al:
Prostate-specific deletion of the murine Pten tumor suppressor gene
leads to metastatic prostate cancer. Cancer Cell. 4:209–221. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mulholland DJ, Kobayashi N, Ruscetti M, et
al: Pten loss and RAS/MAPK activation cooperate to promote EMT and
metastasis initiated from prostate cancer stem/progenitor cells.
Cancer Res. 72:1878–1889. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McCubrey JA, Steelman LS, Abrams SL, et
al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in
malignant transformation and drug resistance. Adv Enzyme Regul.
46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rao J and Li N: Microfilament actin
remodeling as a potential target for cancer drug development. Curr
Cancer Drug Targets. 4:345–354. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giganti A and Friederich E: The actin
cytoskeleton as a therapeutic target: state of the art and future
directions. Prog Cell Cycle Res. 5:511–525. 2003.PubMed/NCBI
|
|
9
|
Coue M, Brenner SL, Spector I and Korn ED:
Inhibition of actin polymerization by latrunculin A. FEBS Lett.
213:316–318. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ayscough KR, Stryker J, Pokala N, Sanders
M, Crews P and Drubin DG: High rates of actin filament turnover in
budding yeast and roles for actin in establishment and maintenance
of cell polarity revealed using the actin inhibitor latrunculin-A.
J Cell Biol. 137:399–416. 1997. View Article : Google Scholar
|
|
11
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim JS, Xu X, Li H, et al: Mechanistic
analysis of a DNA damage-induced, PTEN-dependent size checkpoint in
human cells. Mol Cell Biol. 31:2756–2771. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ming M, Feng L, Shea CR, et al: PTEN
positively regulates UVB-induced DNA damage repair. Cancer Res.
71:5287–5295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ming M and He YY: PTEN in DNA damage
repair. Cancer Lett. 319:125–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shin IJ, Ahn YT, Kim Y, Kim JM and An WG:
Actin disruption agents induce phosphorylation of histone H2AX in
human breast adenocarcinoma MCF-7 cells. Oncol Rep. 25:1313–1319.
2011.PubMed/NCBI
|
|
16
|
Shin IJ, Park BK, Ahn YT, Kim Y and An WG:
Actin disruption inhibits hypoxia inducible factor-1alpha
expression via inactivity of Mdm2-mediated p70S6K. Mol Med Report.
3:815–819. 2010.PubMed/NCBI
|
|
17
|
van Gent DC, Hoeijmakers JH and Kanaar R:
Chromosomal stability and the DNA double-stranded break connection.
Nat Rev Genet. 2:196–206. 2001.
|
|
18
|
Labi V, Grespi F, Baumgartner F and
Villunger A: Targeting the Bcl-2-regulated apoptosis pathway by BH3
mimetics: a breakthrough in anticancer therapy? Cell Death Differ.
15:977–987. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rogakou EP, Pilch DR, Orr AH, Ivanova VS
and Bonner WM: DNA double-stranded breaks induce histone H2AX
phosphorylation on serine 139. J Biol Chem. 273:5858–5868. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Downs JA, Allard S, Jobin-Robitaille O, et
al: Binding of chromatin-modifying activities to phosphorylated
histone H2A at DNA damage sites. Mol Cell. 16:979–990. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang D, Wu D, Hirao A, et al: ERK
activation mediates cell cycle arrest and apoptosis after DNA
damage independently of p53. J Biol Chem. 277:12710–12717. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee K and Song K: Actin dysfunction
activates ERK1/2 and delays entry into mitosis in mammalian cells.
Cell Cycle. 6:1487–1495. 2007.PubMed/NCBI
|
|
24
|
Gachet Y, Tournier S, Millar JB and Hyams
JS: A MAP kinase-dependent actin checkpoint ensures proper spindle
orientation in fission yeast. Nature. 412:352–355. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rupes I, Webb BA, Mak A and Young PG: G2/M
arrest caused by actin disruption is a manifestation of the cell
size checkpoint in fission yeast. Mol Biol Cell. 12:3892–3903.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Favata MF, Horiuchi KY, Manos EJ, et al:
Identification of a novel inhibitor of mitogen-activated protein
kinase kinase. J Biol Chem. 273:18623–18632. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jang K, Kim M, Seo HS and Shin I: PTEN
sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for
the blockade of cell proliferation. Oncol Rep. 24:787–793.
2010.PubMed/NCBI
|
|
28
|
McCubrey JA, Steelman LS, Chappell WH, et
al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
